Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: Role of vanilloid receptors and lipoxygenases

Journal of Neuroscience

Volumn 23, Issue 10, 2003, Pages 4127-4133

  Veldhuis, W B ^a,b   Van der Stelt, M ^c,e   Wadman, M W ^c   Van Zadelhoff, G ^c   Maccarrone, M ^d   Fezza, F ^e   Veldink, G A ^c   Vliegenthart, J F G ^c   Bar P R ^b   Nicolay, K ^a   Di Marzo, V ^e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF TERAMO   (Italy)

^e CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Anandamide; Arvanil; Cannabinoid; CNS; Excitotoxicity; Neurodegeneration; Neuroprotection; Ouabain; Vanilloid

Indexed keywords

12 HYDROXY N ARACHIDONOYLETHANOLAMINE; 15 HYDROXY N ARACHIDONOYLETHANOLAMINE; ANANDAMIDE; ARVANIL; CANNABINOID; CANNABINOID 1 RECEPTOR; CAPSAICIN; LIGAND; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NORDIHYDROGUAIARETIC ACID; OUABAIN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; AMIDE; ARACHIDONIC ACID DERIVATIVE; DRUG DERIVATIVE; DRUG RECEPTOR; ENDOCANNABINOID; ETHANOLAMINE DERIVATIVE; NEUROPROTECTIVE AGENT; UNSATURATED FATTY ACID;

ANIMAL TISSUE; ARTICLE; BLOOD CELL; BRAIN EDEMA; CONTROLLED STUDY; CYTOTOXICITY; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; IN VIVO STUDY; MALE; MASS SPECTROMETRY; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; RECEPTOR INTRINSIC ACTIVITY; ANIMAL; BRAIN; BRAIN LEVEL; BRAIN MAPPING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYMOLOGY; METABOLISM; NEWBORN; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; ARACHIDONIC ACIDS; BLOOD CELLS; BRAIN; BRAIN CHEMISTRY; BRAIN MAPPING; CANNABINOIDS; CAPSAICIN; ENDOCANNABINOIDS; ETHANOLAMINES; FATTY ACIDS, UNSATURATED; LIPOXYGENASE; MALE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; NORDIHYDROGUAIARETIC ACID; OUABAIN; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; RECEPTORS, DRUG;

EID: 0037704448     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-10-04127.2003     Document Type: Article

References (58)

1. Adams IB, Compton DR, Martin BR (1998) Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217.
2. Annunziata P, Cioni C, Santonini R, Paccagnini E (2002) Substance P antagonist block leakage and reduces activation of cytokine-stimulated rat brain endothelium. J Neuroimmunol 131:41-49.
3. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z (1995) The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 375:143-147.
4. Bligh E, Dyer W (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-920.
5. Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJ, Brown P, Bridges D, Ledent C, Bifulco M, Rice AS, Di Marzo V, Baker D (2002) Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur J Pharmacol 439:83-92.
6. Craib SJ, Ellington HC, Pertwee RG, Ross RA (2001) A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br J Pharmacol 134:30-37.
7. de Graaf RA, Braun KP, Nicolay K (2001) Single-shot diffusion trace (1)HNMR spectroscopy. Magn Reson Med 45:741-748.
8. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
9. Di Marzo V, Melck D, Bisogno T, De Petrocellis L (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21:521-528.
10. Di Marzo V, Breivogel C, Bisogno T, Melck D, Patrick G, Tao Q, Szallasi A, Razdan RK, Martin BR (2000) Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. Eur J Pharmacol 406:363-374.
11. Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB, Fernandez-Ruiz JJ (2001a) Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharmacol 420:123-131.
12. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL, Davis JB, Dasse O, Mahadevan A, Razdan RK, Martin BR (2001b) Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Biochem Biophys Res Commun 281:444-451.
13. Di Marzo V, Griffin G, De Petrocellis L, Brandi I, Bisogno T, Williams W, Grier MC, Kulasegram S, Mahadevan A, Razdan RK, Martin BR (2002) A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J Pharmacol Exp Ther 300:984-991.
14. Dib B, Falchi M (1996) Convulsions and death induced in rats by Tween 80 are prevented by capsaicin. Int J Tissue React 18:27-31.
15. Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB (1998) Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 54:180-188.
16. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW (2000) Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 57:1045-1050.
17. Hajos N, Freund T (2002) Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43:503-510.
18. Hajos M, Jancso G, Engberg G (1987) Capsaicin-induced excitation of locus coeruleus neurons. Acta Physiol Scand 129:415-420.
19. Hajos M, Engberg G, Nissbrandt H, Magnusson T, Carlsson A (1988) Capsaicin-sensitive vasodilatatory mechanisms in the rat substantia nigra and striatum. J Neural Transm 74:129-139.
20. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99:8400-8405.
21. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, Cho S, Min KH, Suh YG, Kim D, Oh U (2000) Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 97:6155-6160.
22. Jung YS, Cho TS, Moon CH, Shin HS (1998) Capsaicin-induced desensitization is prevented by capsazepine but not by ruthenium red in guinea pig bronchi. Eur J Pharmacol 362:193-198.
23. Jung YS, Cho TS, Moon CH, Lee B, Lee SM, Shin HS (1999) Systemically administered capsazepine prevents the capsaicin-induced functional desensitization and loss of substance P-like immunoreactivity (SP-LI) in guinea-pig bronchi. Life Sci 64:PL173-PL177.
24. Kagaya M, Lamb J, Robbins J, Page CP, Spina D (2002) Characterization of the anandamide induced depolarization of guinea-pig isolated vagus nerve. Br J Pharmacol 137:39-48.
25. Liu L, Oortgiesen M, Li L, Simon SA (2001) Capsaicin inhibits activation of voltage-gated sodium currents in capsaicin-sensitive trigeminal ganglion neurons. J Neurophysiol 85:745-758.
26. Maggi CA (1995) Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. Prog Neurobiol 45:1-98.
27. Marinelli S, Vaughan CW, Christie MJ, Connor M (2002) Capsaicin activation of glutamatergic synaptic transmission in the rat locus coeruleus in vitro. J Physiol (Lond) 543:531-540.
28. Martin FC, Charles AC, Sanderson MJ, Merrill JE (1992) Substance P stimulates IL-1 production by astrocytes via intracellular calcium. Brain Res 599:13-18.
29. McLean PG, Aston D, Sarkar D, Ahluwalia A (2002) Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers. Circ Res 90:465-472.
30. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90.
31. Mechoulam R, Fride E, Di Marzo V (1998) Endocannabinoids. Eur J Pharmacol 359:1-18.
32. Mechoulam R, Spatz M, Shohami E (2002) Endocannabinoids and neuroprotection. Sci STKE 2002:RE5.
33. Melck D, Bisogno T, De Petrocellis L, Chuang H, Julius D, Bifulco M, Di Marzo V (1999) Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 262:275-284.
34. Mezey E, Toth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, Guo A, Blumberg PM, Szallasi A (2000) Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 97:3655-3660.
35. Miyamoto T, Lindgren JA, Samuelsson B (1987) Isolation and identification of lipoxygenase products from the rat central nervous system. Biochim Biophys Acta 922:372-378.
36. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19:2987-2995.
37. Nicol GD, Lopshire JC, Pafford CM (1997) Tumor necrosis factor enhances the capsaicin sensitivity of rat sensory neurons. J Neurosci 17:975-982.
38. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527-531.
39. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA (2002) Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 22:9771-9775.
40. Sanchez JF, Krause JE, Cortright DN (2001) The distribution and regulation of vanilloid receptor VR1 and VR1 5′ splice variant RNA expression in rat. Neuroscience 107:373-381.
41. Sancho R, Lucena C, Macho A, Calzado MA, Blanco-Molina M, Minassi A, Appendino G, Munoz E (2002) Immunosuppressive activity of capsaicinoids: capsiate derived from sweet peppers inhibits NF-kappaB activation and is a potent antiinflammatory compound in vivo. Eur J Immunol 32:1753-1763.
42. Shin J, Cho H, Hwang SW, Jung J, Shin CY, Lee SY, Kim SH, Lee MG, Choi YH, Kim J, Haber NA, Reichling DB, Khasar S, Levine JD, Oh U (2002) Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. Proc Natl Acad Sci USA 99:10150-10155.
43. Shishido Y, Furushiro M, Hashimoto S, Yokokura T (2001) Effect of nordihydroguaiaretic acid on behavioral impairment and neuronal cell death after forebrain ischemia. Pharmacol Biochem Behav 69:469-474.
44. Sinor AD, Irvin SM, Greenberg DA (2000) Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 278:157-160.
45. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, Randall AD, Davis JB (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129:227-230.
46. Sugiura T, Tominaga M, Katsuya H, Mizumura K (2002) Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor 1. J Neurophysiol 88:544-548.
47. Szabo T, Biro T, Gonzalez AF, Palkovits M, Blumberg PM (2002) Pharmacological characterization of vanilloid receptor located in the brain. Brain Res Mol Brain Res 98:51-57.
48. Szallasi A, Blumberg PM (1999) Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 51:159-212.
49. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D (1998) The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21:531-543.
50. van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JF, Nicolay K (2001a) Neuroprotection by Δ9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 21:6475-6479.
51. van der Stelt M, Veldhuis WB, van Haaften GW, Fezza F, Bisogno T, Bar PR, Veldink GA, Vliegenthart JF, Di Marzo V, Nicolay K (2001b) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 21:8765-8771.
52. van der Stelt M, Veldhuis WB, Maccarrone M, Bar PR, Nicolay K, Veldink GA, Di Marzo V, Vliegenthart JF (2002a) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26:317-346.
53. van der Stelt M, van Kuik JA, Bari M, van Zadelhoff G, Leeflang BR, Veldink GA, Finazzi-Agro A, Vliegenthart JF, Maccarrone M (2002b) Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem 45:3709-3720.
54. van Zadelhoff G, Veldink GA, Vliegenthart JF (1998) With anandamide as substrate plant 5-lipoxygenases behave like 11-lipoxygenases. Biochem Biophys Res Commun 248:33-38.
55. +-ATPase inhibitor. J Cereb Blood Flow Metab 23:62-74.
56. Vyklicky L, Knotkova-Urbancova H, Vitaskova Z, Vlachova V, Kress M, Reeh PW (1998) Inflammatory mediators at acidic pH activate capsaicin receptors in cultured sensory neurons from newborn rats. J Neurophysiol 79:670-676.
57. Willoughby KA, Moore SF, Martin BR, Ellis EF (1997) The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282:243-247.
58. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457.